focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Germany warns vaccinations alone will not contain COVID-19 third wave

Fri, 19th Mar 2021 12:41

* Spahn says doctors will now be more informed of risks

* Merkel to discuss speeding up rollout with state leaders

* Spahn says would favour supply deal for Russia's Sputnik V
(Adds details)

BERLIN, March 19 (Reuters) - Germany's health minister
warned on Friday there was not enough vaccine in Europe to
contain the COVID-19 third wave, as the country sought to get
its rollout back on track following a three-day pause in using
the AstraZeneca shot.

Case numbers have been rising in Germany, driven by an
easing of restrictions in recent weeks just as a more
transmissible variant of the virus has spread, underlining the
need to accelerate vaccinations to protect the vulnerable.

Health Minister Jens Spahn defended the suspension, which
was lifted on Thursday after European Union regulators said the
benefits outweighed the risk, as providing
transparency.

"We can reintroduce AstraZeneca but prudently with informed
doctors and appropriately educated citizens," he said in a
weekly news conference.

But he warned that vaccinations alone would not be able to
contain the third wave as there are not enough doses, and said
restrictions that were lifted may have to be reimposed to
contain the spread of the virus.

"The rising case numbers may mean that we cannot take
further opening steps in the weeks to come. On the contrary, we
may even have to take steps backwards," Spahn said.

State leaders are also due to discuss with Chancellor Angela
Merkel later on Friday ways to speed up the vaccination
campaign, among other by allowing family doctors to start
administering doses at their surgeries.

The suspension was the latest hurdle in Germany's
vaccination campaign, which has been plagued by delivery delays
and news reports of side-effects. As of Friday, just 8.5% of the
population had received a first shot, far behind other countries
like the United States and Britain.

German state leaders said they were ready to quickly catch
up on lost time. In Berlin, anyone who was due to receive an
AstraZeneca shot earlier in the week can turn up at vaccination
centres this weekend without an appointment.

YOUNGER WOMEN

Meanwhile, the premier of the southwestern German state of
Baden-Wuerttemberg, Winfried Kretschmann, 72, is due to receive
an AstraZeneca vaccination on Friday, in a move to shore up
confidence.

But Bodo Ramelow, the premier of Thuringia in eastern
Germany, said he would not advise his wife, who needs to use
blood thinners due to a risk of thrombosis, to get the
AstraZeneca shot although he would do so himself.

Karl Lauterbach, the main health expert of the SPD, Merkel's
junior coalition partner, said it was important to not create
the impression that the AstraZeneca vaccine was not suitable for
younger women.

In Germany, eight people were diagnosed with cerebral venous
sinus thrombosis (CVST) within about two weeks of being
vaccinated. They were among the 1.6 million recipients of the
shot as of Wednesday, with CVST cases higher among women.

Lauterbach said the higher incidence could be due to the
fact that younger women work in the health sector or in
kindergartens, groups that have received the AstraZeneca vaccine
in higher numbers.

Spahn said he hoped vaccinations could take place in
doctors' practices from April 19 at the latest, but warned that
supply would remain restricted.

Germany expects to receive 15 million doses of the
AstraZeneca vaccine in the second quarter, a few million fewer
than initially expected, he said.

Spahn also spoke out in favour of signing a supply deal for
the Russian Sputnik V vaccine for COVID-19, but said there
needed to be greater clarity on the quantities available.

(Reporting by Caroline Copley; Editing by Maria Sheahan and
Paul Simao)

More News
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.